- Conditions
- COPD, Chronic Obstructive Pulmonary Disease, Chronic Obstructive Pulmonary Disease Severe, Chronic Obstructive Pulmonary Disease Moderate
- Interventions
- Wellinks
- Other
- Lead sponsor
- Convexity Scientific Inc
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 153 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022
- U.S. locations
- 2
- States / cities
- New Haven, Connecticut • Washington D.C., District of Columbia
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 2641–2664
of 4,737
matching trials from the live ClinicalTrials.gov search.
- Conditions
- COPD
- Interventions
- Glycopyrronium and Formoterol Fumarate Metered-dose Inhaler
- Drug
- Lead sponsor
- Pearl Therapeutics, Inc.
- Industry
- Eligibility
- 40 Years to 80 Years
- Enrollment
- 138 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2015
- U.S. locations
- 10
- States / cities
- Clearwater, Florida • Tampa, Florida • Winter Park, Florida + 7 more
- Conditions
- Snoring, Mouth Breathing, Daytime Sleepiness, Periodontitis
- Interventions
- Oral appliance therapy plus scaling and root planing on left or right of mouth
- Device
- Lead sponsor
- Texas A&M University
- Other
- Eligibility
- 18 Years to 85 Years
- Enrollment
- 43 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2024 – 2025
- U.S. locations
- 1
- States / cities
- Dallas, Texas
- Conditions
- Healthy Adults, Stress
- Interventions
- Slow breathing
- Behavioral
- Lead sponsor
- Vanderbilt University Medical Center
- Other
- Eligibility
- 30 Years to 60 Years
- Enrollment
- 99 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2016 – 2018
- U.S. locations
- 1
- States / cities
- Nashville, Tennessee
- Conditions
- Gastroesophageal Reflux
- Interventions
- Dexlansoprazole MR
- Drug
- Lead sponsor
- Takeda
- Industry
- Eligibility
- 12 Years to 17 Years
- Enrollment
- 36 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009
- U.S. locations
- 3
- States / cities
- Anaheim, California • Cypress, California • Overland Park, Kansas
- Conditions
- Cardiac Arrest (CA)
- Interventions
- Precision-Controlled Ventilation with Real-Time Feedback, Standard Manual Ventilation During CPR
- Device · Other
- Lead sponsor
- Rush University Medical Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 852 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2030
- U.S. locations
- 1
- States / cities
- Chicago, Illinois
- Conditions
- Pneumonia, Pneumocystis Carinii, HIV Infections
- Interventions
- Pentamidine isethionate, Pyrimethamine, Sulfamethoxazole/Trimethoprim, Sulfadoxine/Pyrimethamine, Zidovudine
- Drug
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 12 Years and older
- Enrollment
- 322 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Ends 1991
- U.S. locations
- 9
- States / cities
- Los Angeles, California • San Diego, California • San Francisco, California + 6 more
- Conditions
- Respiratory Complications, Opioid Induced Respiratory Depression, Postoperative Respiratory Complications
- Interventions
- Respiratory volume monitoring
- Diagnostic Test
- Lead sponsor
- Wayne State University
- Other
- Eligibility
- 18 Years to 85 Years
- Enrollment
- 52 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2026 – 2029
- U.S. locations
- 1
- States / cities
- Detroit, Michigan
- Conditions
- Pulmonary Disease, Chronic Obstructive
- Interventions
- Tiotropium Bromide, Fluticasone Propionate/Salmeterol
- Drug
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 40 Years to 99 Years
- Enrollment
- 342 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2009
- U.S. locations
- 35
- States / cities
- Riverside, California • Fort Collins, Colorado • Clearwater, Florida + 31 more
- Conditions
- Facial Pain, Rhinosinusitis
- Interventions
- Erenumab Prefilled Syringe, Placebo
- Drug · Other
- Lead sponsor
- David Jang, M.D.
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 29 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2023
- U.S. locations
- 1
- States / cities
- Durham, North Carolina
- Conditions
- Idiopathic Pulmonary Fibrosis
- Interventions
- Atezolizumab
- Drug
- Lead sponsor
- Cedars-Sinai Medical Center
- Other
- Eligibility
- 50 Years to 80 Years
- Enrollment
- 24 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2027
- U.S. locations
- 1
- States / cities
- Los Angeles, California
- Conditions
- COVID-19, Atrial Fibrillation New Onset
- Interventions
- ILR, PMK, ICD
- Device
- Lead sponsor
- Texas Cardiac Arrhythmia Research Foundation
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 200 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2023
- U.S. locations
- 2
- States / cities
- Kansas City, Kansas • Austin, Texas
- Conditions
- Long COVID, Post-COVID Syndrome, Post COVID-19 Condition
- Interventions
- REGENECYTE, Placebo
- Biological
- Lead sponsor
- StemCyte, Inc.
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2025
- U.S. locations
- 1
- States / cities
- Miami Lakes, Florida
- Conditions
- Carcinoma, Non-Small-Cell Lung, Small Cell Lung Carcinoma, Endometrial Neoplasms, Neoplasm Metastasis, Triple Negative Breast Cancer
- Interventions
- LY4175408, Pembrolizumab, Carboplatin, Cisplatin
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 240 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2030
- U.S. locations
- 15
- States / cities
- Stanford, California • Orlando, Florida • Sarasota, Florida + 11 more
- Conditions
- Alpha 1-Antitrypsin Deficiency
- Interventions
- VX-814, Placebo
- Drug
- Lead sponsor
- Vertex Pharmaceuticals Incorporated
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 48 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020
- U.S. locations
- 22
- States / cities
- Birmingham, Alabama • Sacramento, California • Denver, Colorado + 19 more
- Conditions
- Cough, Myalgia, Nasal Obstruction, Sore Throat, Headache, Fatigue, Fever
- Interventions
- Not listed
- Lead sponsor
- Cellex, Inc.
- Industry
- Eligibility
- Not listed
- Enrollment
- 506 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2012
- U.S. locations
- 3
- States / cities
- Birmingham, Alabama • Chicago, Illinois • Baltimore, Maryland
- Conditions
- COPD, COPD - Chronic Obstructive Pulmonary Disease
- Interventions
- Activated ROAM System with User Feedback, Sham Comparator
- Device
- Lead sponsor
- Barron Associates, Inc.
- Industry
- Eligibility
- 21 Years and older
- Enrollment
- 100 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2026
- U.S. locations
- 1
- States / cities
- Charlottesville, Virginia
- Conditions
- Critical Illness, Acute Respiratory Failure
- Interventions
- Olimel (5.7%E / N9E)
- Drug
- Lead sponsor
- Clinical Evaluation Research Unit at Kingston General Hospital
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 125 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2015
- U.S. locations
- 7
- States / cities
- Boulder, Colorado • St Louis, Missouri • Cleveland, Ohio + 3 more
- Conditions
- Obesity
- Interventions
- Lorcaserin 10 mg once daily (QD), Lorcaserin 10 mg twice a day (BID), Matching Placebo
- Drug
- Lead sponsor
- Eisai Inc.
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 4,008 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2009
- U.S. locations
- 1
- States / cities
- San Diego, California
- Conditions
- Pulmonary Disease, Chronic Obstructive, Bronchitis, Chronic
- Interventions
- BIBW 2948 BS, Placebo
- Drug
- Lead sponsor
- Boehringer Ingelheim
- Industry
- Eligibility
- 40 Years to 70 Years
- Enrollment
- 48 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2008
- U.S. locations
- 4
- States / cities
- Birmingham, Alabama • San Francisco, California • Denver, Colorado + 1 more
- Conditions
- Pulmonary Disease, Chronic Obstructive
- Interventions
- Atrovent Respimat (20 mcg), COMBIVENT MDI (36/206 mcg), Combivent Respimat (20 mcg/100 mcg), Placebo via corresponding inhaler for blinding purposes
- Drug
- Lead sponsor
- Boehringer Ingelheim
- Industry
- Eligibility
- 40 Years and older
- Enrollment
- 1,480 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2006
- U.S. locations
- 87
- States / cities
- Birmingham, Alabama • Jasper, Alabama • Mobile, Alabama + 74 more
- Conditions
- Respiratory Failure, Infant, Persistent Fetal Circulation
- Interventions
- inhaled Nitric Oxide, Oxygen (>90% by hood) - standard therapy
- Drug
- Lead sponsor
- University of Alabama at Birmingham
- Other
- Eligibility
- 1 Hour to 1 Week
- Enrollment
- 8 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1999 – 2005
- U.S. locations
- 1
- States / cities
- Birmingham, Alabama
- Conditions
- Hematologic Malignancy, GvHD, GVHD,Acute, GVHD, Chronic, Hematopoietic Stem Cell Transplant, Acute Lymphoblastic Leukemia, Adult B-Cell, Acute Lymphoblastic Leukemia, Adult T-Cell, Acute Myeloid Leukemia in Remission, Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, in Remission, Cancer Remission
- Interventions
- TRX103
- Biological
- Lead sponsor
- Tr1X, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 36 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2027
- U.S. locations
- 5
- States / cities
- Duarte, California • Boston, Massachusetts • Minneapolis, Minnesota + 2 more
- Conditions
- Esophageal Atresia, Tracheoesophageal Fistula
- Interventions
- Transanastomotic Tube (5FR), No Transanastomotic Tube
- Device · Other
- Lead sponsor
- Phoenix Children's Hospital
- Other
- Eligibility
- Up to 6 Months
- Enrollment
- 141 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2029
- U.S. locations
- 10
- States / cities
- Phoenix, Arizona • Los Angeles, California • San Diego, California + 7 more